1Department of Pharmacology, Noida Institute of Engineering and Technology (Pharmacy Institute), 19, Knowledge Park-II, Greater Noida, 201306 Uttar Pradesh, India
2School of Pharmaceutical Science, Lovely Professional University, Jalandhar-Delhi, G.T. Road Phagwara, Punjab, 144411, India
*Corresponding author: Dr. Saumya Das, Noida Institute of Engineering and Technology (Pharmacy Institute), 19, Knowledge Park-II, Greater Noida, 201306, Uttar Pradesh, India. Phone: 9911940620; Email: awasthi.saumya22@gmail.com; ORCID: 0000-0002-8531-9963
Background: Gastroesophageal reflux disease (GERD) is a chronic gastroenterological disorder resulting from the backward flow of gastric contents into the esophagus, clinical manifestations of which may include heartburn and regurgitation, with complications including erosive esophagitis and Barrett's esophagus. While proton pump inhibitors (PPIs) are broadly used as first-line, limitations around incomplete symptom relief and long-term dependence illustrate the need for better treatment strategies.
Objective: Controlled delivery systems for targeted drugs are a novel approach to increase drug stability and long-term gastric residence time, site-specific action, and prolong therapeutic effects of the system.
Findings: It has been established that various systems including mucoadhesive formulations, pH-responsive carriers, raft-forming systems, gastroretentive drug delivery systems and nanotechnology-based carriers, are able to achieve higher bioavailability on GERD management which leads to therapeutic efficacy enhancement and patient compliance improvement.
Keywords: Gastroesophageal reflux disease, Targeted drug delivery Controlled release, Gastroretentive systems, Nanoparticles, Proton pump inhibitors.
How to cite this article: Chauhan K, Das S, Mazumder A, Chaitanya M. Targeted and Controlled Drug Delivery Approaches in the Management of Gastroesophageal Reflux Disease. Int J Drug Deliv Technol. 2026;16(12s): 665-675. DOI: 10.25258/ijddt.16.12s.79
Source of support: Nil.
Conflict of interest: None